The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) HER2 testing guideline for breast cancer (2007) was the first evidence‐based guideline that directly addressed the necessity of controlling pre‐analytical variables for biospecimens in cancer biomarker testing [34]. This evidence concerns the gene ERBB2 and cancer.